Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Retraction notice to "SRI36160 is a specific inhibitor of Wnt/-catenin signaling in human pancreatic and colorectal cancer cells" [Canc. Lett. 389C (2017) 41-48].

Li Y, Oliver PG, Lu W, Pathak V, Sridharan S, Augelli-Szafran CE, Buchsbaum DJ, Suto MJ.

Cancer Lett. 2018 May 28;422:131. doi: 10.1016/j.canlet.2018.03.017. No abstract available.

2.

Thrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease.

Murphy-Ullrich JE, Suto MJ.

Matrix Biol. 2017 Dec 27. pii: S0945-053X(17)30359-1. doi: 10.1016/j.matbio.2017.12.009. [Epub ahead of print] Review.

PMID:
29288716
3.

Discovery of novel frizzled-7 inhibitors by targeting the receptor's transmembrane domain.

Zhang W, Lu W, Ananthan S, Suto MJ, Li Y.

Oncotarget. 2017 Sep 6;8(53):91459-91470. doi: 10.18632/oncotarget.20665. eCollection 2017 Oct 31.

4.

Predicting radiotherapy response for patients with soft tissue sarcoma by developing a molecular signature.

Tang Z, Zeng Q, Li Y, Zhang X, Suto MJ, Xu B, Yi N.

Oncol Rep. 2017 Nov;38(5):2814-2824. doi: 10.3892/or.2017.5999. Epub 2017 Sep 25.

5.

Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit.

Oliva CR, Zhang W, Langford C, Suto MJ, Griguer CE.

Oncotarget. 2017 Jun 6;8(23):37568-37583. doi: 10.18632/oncotarget.17247.

6.

Development of a radiosensitivity gene signature for patients with soft tissue sarcoma.

Tang Z, Zeng Q, Li Y, Zhang X, Ma J, Suto MJ, Xu B, Yi N.

Oncotarget. 2017 Apr 18;8(16):27428-27439. doi: 10.18632/oncotarget.16194.

7.

Retraction of "Design and Synthesis of Novel Cyclic Amine Benzimidazoles for the Treatment of Pancreatic Cancer".

Pathak V, Augelli-Szafran CE, Wei HX, Li Y, Oliver PG, Lu W, Buchsbaum DJ, Suto MJ.

J Med Chem. 2017 Sep 14;60(17):7615. doi: 10.1021/acs.jmedchem.6b01417. No abstract available.

PMID:
28230988
8.

SRI36160 is a specific inhibitor of Wnt/β-catenin signaling in human pancreatic and colorectal cancer cells.

Li Y, Oliver PG, Lu W, Pathak V, Sridharan S, Augelli-Szafran CE, Buchsbaum DJ, Suto MJ.

Cancer Lett. 2017 Mar 28;389:41-48. doi: 10.1016/j.canlet.2016.12.030. Epub 2016 Dec 30. Retraction in: Cancer Lett. 2018 May 28;422:131.

9.

Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations.

Mutyam V, Du M, Xue X, Keeling KM, White EL, Bostwick JR, Rasmussen L, Liu B, Mazur M, Hong JS, Falk Libby E, Liang F, Shang H, Mense M, Suto MJ, Bedwell DM, Rowe SM.

Am J Respir Crit Care Med. 2016 Nov 1;194(9):1092-1103.

10.

Effective self-management strategies for bipolar disorder: A community-engaged Delphi Consensus Consultation study.

Michalak EE, Suto MJ, Barnes SJ, Hou S, Lapsley S, Scott MW, Murray G, Austin J, Elliott NB, Berk L, Crest Bd.

J Affect Disord. 2016 Dec;206:77-86. doi: 10.1016/j.jad.2016.06.057. Epub 2016 Jul 11.

PMID:
27466745
11.

Identification of Small Molecule Inhibitors of Human Cytochrome c Oxidase That Target Chemoresistant Glioma Cells.

Oliva CR, Markert T, Ross LJ, White EL, Rasmussen L, Zhang W, Everts M, Moellering DR, Bailey SM, Suto MJ, Griguer CE.

J Biol Chem. 2016 Nov 11;291(46):24188-24199. Epub 2016 Sep 27.

12.

Consortia's critical role in developing medical countermeasures for re-emerging viral infections: a USA perspective.

Everts M, Suto MJ, Painter GR, Whitley RJ.

Future Virol. 2016 Mar;11(3):187-195. Epub 2016 Feb 29.

13.

Discovery of a novel inhibitor of kinesin-like protein KIFC1.

Zhang W, Zhai L, Wang Y, Boohaker RJ, Lu W, Gupta VV, Padmalayam I, Bostwick RJ, White EL, Ross LJ, Maddry J, Ananthan S, Augelli-Szafran CE, Suto MJ, Xu B, Li R, Li Y.

Biochem J. 2016 Apr 15;473(8):1027-35. doi: 10.1042/BJ20150992. Epub 2016 Feb 4.

14.

Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma.

Lu A, Pallero MA, Lei W, Hong H, Yang Y, Suto MJ, Murphy-Ullrich JE.

Am J Pathol. 2016 Mar;186(3):678-90. doi: 10.1016/j.ajpath.2015.11.003. Epub 2016 Jan 20.

15.

Peer support as a catalyst for recovery: a mixed-methods study.

Wrobleski T, Walker G, Jarus-Hakak A, Suto MJ.

Can J Occup Ther. 2015 Feb;82(1):64-73.

PMID:
25803949
16.

Unique functional and structural properties of the LRRK2 protein ATP-binding pocket.

Liu Z, Galemmo RA Jr, Fraser KB, Moehle MS, Sen S, Volpicelli-Daley LA, DeLucas LJ, Ross LJ, Valiyaveettil J, Moukha-Chafiq O, Pathak AK, Ananthan S, Kezar H, White EL, Gupta V, Maddry JA, Suto MJ, West AB.

J Biol Chem. 2014 Nov 21;289(47):32937-51. doi: 10.1074/jbc.M114.602318. Epub 2014 Sep 16.

17.

AlphaScreen HTS and live-cell bioluminescence resonance energy transfer (BRET) assays for identification of Tau-Fyn SH3 interaction inhibitors for Alzheimer disease.

Cochran JN, Diggs PV, Nebane NM, Rasmussen L, White EL, Bostwick R, Maddry JA, Suto MJ, Roberson ED.

J Biomol Screen. 2014 Dec;19(10):1338-49. doi: 10.1177/1087057114547232. Epub 2014 Aug 25.

18.

Spirituality in bedlam: exploring professional conversations on acute psychiatric units.

Suto MJ, Smith S.

Can J Occup Ther. 2014 Feb;81(1):18-28.

PMID:
24783485
19.

Spirituality in bedlam: exploring patient conversations on acute psychiatric units.

Smith S, Suto MJ.

Can J Occup Ther. 2014 Feb;81(1):8-17.

PMID:
24783484
20.

Well-being and engagement in valued activities: experiences of young people with psychosis.

Lal S, Ungar M, Leggo C, Malla A, Frankish J, Suto MJ.

OTJR (Thorofare N J). 2013 Fall;33(4):190-7. doi: 10.3928/15394492-20130912-02.

PMID:
24652027
21.

A scoping review of the Photovoice method: implications for occupational therapy research.

Lal S, Jarus T, Suto MJ.

Can J Occup Ther. 2012 Jun;79(3):181-90. Review.

PMID:
22822696
22.
23.

Frizzled7 as an emerging target for cancer therapy.

King TD, Zhang W, Suto MJ, Li Y.

Cell Signal. 2012 Apr;24(4):846-51. doi: 10.1016/j.cellsig.2011.12.009. Epub 2011 Dec 13. Review.

24.

The Wnt/β-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer.

King TD, Suto MJ, Li Y.

J Cell Biochem. 2012 Jan;113(1):13-8. doi: 10.1002/jcb.23350. Review.

PMID:
21898546
25.

N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy.

Amato G, Roeloffs R, Rigdon GC, Antonio B, Mersch T, McNaughton-Smith G, Wickenden AD, Fritch P, Suto MJ.

ACS Med Chem Lett. 2011 Mar 31;2(6):481-4. doi: 10.1021/ml200053x. eCollection 2011 Jun 9.

26.

Design of a gene family screening library targeting G-protein coupled receptors.

Lamb ML, Bradley EK, Beaton G, Bondy SS, Castellino AJ, Gibbons PA, Suto MJ, Grootenhuis PD.

J Mol Graph Model. 2004 Sep;23(1):15-21.

PMID:
15331050
27.

Neuronal nicotinic acetylcholine receptors as drug targets.

Suto MJ, Zacharias N.

Expert Opin Ther Targets. 2004 Apr;8(2):61-4.

PMID:
15102549
28.

Inhibitors of NF-kappaB and AP-1 gene expression: SAR studies on the pyrimidine portion of 2-chloro-4-trifluoromethylpyrimidine-5-[N-(3', 5'-bis(trifluoromethyl)phenyl)carboxamide].

Palanki MS, Erdman PE, Gayo-Fung LM, Shevlin GI, Sullivan RW, Goldman ME, Ransone LJ, Bennett BL, Manning AM, Suto MJ.

J Med Chem. 2000 Oct 19;43(21):3995-4004.

PMID:
11052805
29.

Designing chiral libraries for drug discovery.

Beroza P, Suto MJ.

Drug Discov Today. 2000 Aug;5(8):364-372.

PMID:
10893549
30.

Developments in solution-phase combinatorial chemistry.

Suto MJ.

Curr Opin Drug Discov Devel. 1999 Jul;2(4):377-84.

PMID:
19649966
31.
32.

A novel inhibitor of nuclear factor-kappa B and activator protein-1 transcription factors in T cells suppresses host-versus-graft alloreactivity in vivo.

Morikawa M, Shorthouse RA, Suto MJ, Goldman ME, Morris RE.

Transplant Proc. 1997 Feb-Mar;29(1-2):1269-70. No abstract available.

PMID:
9123300
33.

SP100030 is a novel T-cell-specific transcription factor inhibitor that possesses immunosuppressive activity in vivo.

Goldman ME, Ransone LJ, Anderson DW, Gaarde WA, Suto MJ, Sullivan RW, Shorthouse R, Morikawa M, Morris RE.

Transplant Proc. 1996 Dec;28(6):3106-9. No abstract available.

PMID:
8962204
35.

Quinolone antibacterials containing the new 7-[3-(1-aminoethyl)-1- pyrrolidinyl] side chain: the effects of the 1-aminoethyl moiety and its stereochemical configurations on potency and in vivo efficacy.

Domagala JM, Hagen SE, Joannides T, Kiely JS, Laborde E, Schroeder MC, Sesnie JA, Shapiro MA, Suto MJ, Vanderroest S.

J Med Chem. 1993 Apr 2;36(7):871-82.

PMID:
8385225
36.
37.

Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity.

Suto MJ, Domagala JM, Roland GE, Mailloux GB, Cohen MA.

J Med Chem. 1992 Dec 11;35(25):4745-50.

PMID:
1469702
38.

Pharmacologic/pharmacokinetic evaluation of emesis induced by analogs of RSU 1069 and its control by antiemetic agents.

Sebolt-Leopold JS, Vincent PW, Beningo KA, Elliott WL, Leopold WR, Heffner TG, Wiley JN, Stier MA, Suto MJ.

Int J Radiat Oncol Biol Phys. 1992;22(3):549-51.

PMID:
1531213
39.

The biochemistry and pharmacology of PD 116124 (8-amino-2'-nordeoxyguanosine), an inhibitor of purine nucleoside phosphorylase (PNP).

Dong MK, Scott ME, Schrier DJ, Suto MJ, Sircar JC, Black A, Chang T, Gilbertsen RB.

J Pharmacol Exp Ther. 1992 Jan;260(1):319-26.

PMID:
1530976
40.

Synthesis and evaluation of a series of 3,5-disubstituted benzisoxazole-4,7-diones. Potent radiosensitizers in vitro.

Suto MJ, Stier MA, Winters RT, Turner WR, Pinter CD, Elliott WE, Sebolt-Leopold JS.

J Med Chem. 1991 Nov;34(11):3290-4.

PMID:
1956048
41.

A new class of analogues of the bifunctional radiosensitizer alpha-(1-aziridinylmethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069): the cycloalkylaziridines.

Suto MJ, Stier MA, Werbel LM, Arundel-Suto CM, Leopold WR, Elliott WE, Sebolt-Leopold JS.

J Med Chem. 1991 Aug;34(8):2484-8.

PMID:
1875345
42.

Effect of PD 128763, a new potent inhibitor of poly(ADP-ribose) polymerase, on X-ray-induced cellular recovery processes in Chinese hamster V79 cells.

Arundel-Suto CM, Scavone SV, Turner WR, Suto MJ, Sebolt-Leopold JS.

Radiat Res. 1991 Jun;126(3):367-71.

PMID:
1903547
43.

Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose) polymerase.

Suto MJ, Turner WR, Arundel-Suto CM, Werbel LM, Sebolt-Leopold JS.

Anticancer Drug Des. 1991 May;6(2):107-17.

PMID:
1903948
46.

1,4-Dihydropyridine antagonist activities at the calcium channel: a quantitative structure-activity relationship approach.

Coburn RA, Wierzba M, Suto MJ, Solo AJ, Triggle AM, Triggle DJ.

J Med Chem. 1988 Nov;31(11):2103-7.

PMID:
2846838
47.

8-Amino-9-substituted guanines: potent purine nucleoside phosphorylase (PNP) inhibitors.

Sircar JC, Kostlan CR, Pinter GW, Suto MJ, Bobovski TP, Capiris T, Schwender CF, Dong MK, Scott ME, Bennett MK, et al.

Agents Actions. 1987 Aug;21(3-4):253-6.

PMID:
3120506
49.

Supplemental Content

Support Center